Abbott Exceeds Earnings Guidance, Strengthens Product Portfolio

Abbott Laboratories reported fourth-quarter earnings that surpassed its own financial guidance for 2022, underscoring a period of robust performance across its diverse business segments. The healthcare giant also highlighted advancements in its medical device portfolio through recent product approvals.

For the fourth quarter, Abbott achieved worldwide sales of $10.1 billion and an adjusted diluted earnings per share of $1.03. Full-year sales reached $43.7 billion, representing a 6.4% organic growth. The company issued its 2023 guidance, projecting adjusted diluted earnings per share between $4.30 and $4.50.

Key highlights from the fourth quarter included FreeStyle Libre systems sales exceeding $1 billion, with U.S. sales growing more than 40%. Additionally, Abbott received FDA approval for its Eterna spinal cord stimulation system, noted as the smallest implantable, rechargeable system for chronic pain management. The FreeStyle Libre systems were also recognized by the Galien Foundation as the "Best Medical Technology" of the past 50 years.

Further strengthening its structural heart portfolio, Abbott also secured FDA approval for the Navitor transcatheter aortic valve implantation system. These developments, alongside continued performance in established pharmaceuticals and medical devices, contributed to the company's positive financial outcome and its outlook for continued growth. Abbott projects 2023 GAAP diluted EPS to be between $3.05 and $3.25.

The company's strong R&D pipeline and strategic product approvals signal a continued focus on expanding its market presence across key healthcare areas, aiming to improve patient outcomes globally.